Robert Shoemaker

Company: Erasca

Job title: Senior Vice President of Research Biology

Seminars:

Exploring Anti-EGFR Therapies for GBM: Case Study of a CNS-penetrant EGFR Inhibitor Developed Specifically for GBM 8:35 am

EGFR is amplified or mutated in ~60% of GBM but previous EGFR inhibitors have not shown promising activity in GBM due to a combination of poor CNS penetration and incomplete inhibition of EGFR signaling. This workshop will gather experts to discuss: Challenges which have previously held back this promising approach using examples from the recent…Read more

day: Workshop Track 2 Pre-Morning Break